Bispecific Antibodies for Lymphoid Malignancy Treatment
by
, , , and
Matteo Bisio
*, 
Luca Legato
,
Filippo Fasano
,
Corrado Benevolo Savelli
,
Carola Boccomini
,
Maura Nicolosi
,
Elisa Santambrogio
,
Roberto Freilone
,
Mattia Novo
and
Barbara Botto
* Hematology Division, A.O.U. Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy
*
Authors to whom correspondence should be addressed.
Cancers 2025, 17(1), 94; https://doi.org/10.3390/cancers17010094
Submission received: 14 October 2024
/
Revised: 30 November 2024
/
Accepted: 10 December 2024
/
Published: 31 December 2024
(This article belongs to the Special Issue Monoclonal Antibodies in Lymphoma)
Simple Summary
Bispecific antibodies (BsAbs) are changing the roadmap in the treatment for B-cell lymphomas, especially in the relapsed/refractory setting. BsAbs are a subtype of bispecific T-cell engagers (BiTEs) which are compounds designed to facilitate T-cell-mediated cell death by redirecting T-cells to attack tumor cells. This review examines the mechanism of action; the available published and ongoing data from clinical trials; and the management of therapy-related adverse events for anti-CD20, CD19, and CD30 BsAbs in the treatment of lymphoid malignancies.
Abstract
Backgroud: The introduction of highly active immunotherapies has changed the outcome of B-cell non-Hodgkin lymphomas (B-NHLs) in the last two decades. Since then, important progress has been shown using newer and more active immunotherapies, including chimeric antigen receptor T-cell therapy (CAR-T), conjugated monoclonal antibodies, and bispecific antobodies, which currently plays a significant role in the treatment of diffuse large B-cell (DLBCL), follicular (FL), and mantle cell (MCL) lymphoma. Purpose: In this review, we provide an updated overview of recently completed and ongoing BsAb trials in patients with relapsed/refractory(R/R) B-NHL and Hodgkin’s lymphoma, including single-agent results, emerging combinations, safety data, and novel constructs. Conclusions: Bispecific antibodies (BsAbs) are a novel class of “off-the-shelf” T-cell-redirecting drugs capable of targeting various cell-surface antigens. New antigen targets are currently under investigation, such as CD19 × CD3 and CD30 × CD3 or CD30 × CD16, in different settings. BsAbs are among the most promising therapeutic options for lymphoma today since they have demonstrated significant single-agent activity, along with a manageable toxicity profile, in patients with heavily pretreated B-NHL.
